Literature DB >> 22525471

Prognosis of hepatocellular carcinoma with portal vein tumor thrombus:assessment based on clinical and computer tomography characteristics.

Lizhong Jia1, Shigeru Kiryu, Takeyuki Watadani, Hiroyuki Akai, Hideomi Yamashita, Masaaki Akahane, Kuni Ohtomo.   

Abstract

Patients with hepatocellular carcinoma (HCC) complicated by portal vein tumor thrombus (PVTT) have an extremely poor prognosis. It is important to select adequate therapeutic options based on reliable prognostic factors using imaging studies and clinical data. Prognostic factors were analyzed in patients with HCC with PVTT in the first branch or main trunk of the portal vein. From 2000 to 2007, 107 consecutive patients with HCC with PVTT in the major portal vein were reviewed, and diagnostic images and clinical characteristics were retrospectively observed. Thirty-eight possible prognostic factors for survival were analyzed by the log-rank test and multivariate analysis using Cox's proportional hazards model. Median overall survival was 14 months following PVTT diagnosis. Survival rates at 6 months, 1, 2, and 3 years were 72.1%, 52.6%, 32.6%, and 29.6%, respectively. Independent prognostic factors for longer survival included:patient age < 65 years, Child-Pugh classification A/B, PVTT treatment, accumulation of Lipiodol in the PVTT after TACE, initial radical treatment for HCC, HCC located in a single lobe of the liver, and no invasion of HCC to the hepatic vein or bile duct. Survival was associated with liver function, tumor extension, and treatment for HCC and PVTT.

Entities:  

Mesh:

Year:  2012        PMID: 22525471     DOI: 10.18926/AMO/48263

Source DB:  PubMed          Journal:  Acta Med Okayama        ISSN: 0386-300X            Impact factor:   0.892


  10 in total

1.  Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.

Authors:  Hai-Hong Ye; Jia-Zhou Ye; Zhi-Bo Xie; Yu-Chong Peng; Jie Chen; Liang Ma; Tao Bai; Jun-Ze Chen; Zhan Lu; Hong-Gui Qin; Bang-De Xiang; Le-Qun Li
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

2.  Clinicopathological predictors of poor survival and recurrence after curative resection in hepatocellular carcinoma without portal vein tumor thrombosis.

Authors:  Li Zhou; Jing-An Rui; Shao-Bin Wang; Shu-Guang Chen; Qiang Qu
Journal:  Pathol Oncol Res       Date:  2014-06-08       Impact factor: 3.201

3.  Genetic variants in the EPCAM gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma with portal vein tumor thrombus.

Authors:  Xiaohe Yu; Naijian Ge; Xu Guo; Shuqun Shen; Jun Liang; Xiaojun Huang; Shaogui Wan; Jingliang Xing; Qichao Huang; Yefa Yang
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

4.  FDG-Avid Portal Vein Tumor Thrombosis from Hepatocellular Carcinoma in Contrast-Enhanced FDG PET/CT.

Authors:  Xuan Canh Nguyen; Dinh Song Huy Nguyen; Van Tan Ngo; Simone Maurea
Journal:  Asia Ocean J Nucl Med Biol       Date:  2015

5.  Comparison of conservative treatment versus transcatheter arterial embolisation for the treatment of spontaneously ruptured hepatocellular carcinoma.

Authors:  Kohei Shinmura; Young Ho Choi; Masashi Shimohira; Yasutaka Baba; Shunichiro Ikeda; Sadao Hayashi; Yuta Shibamoto; Chihaya Koriyama; Takashi Yoshiura
Journal:  Pol J Radiol       Date:  2018-06-22

6.  Resection might be a meaningful choice for hepatocellular carcinoma with portal vein thrombosis: A systematic review and meta-analysis.

Authors:  Zun-Yi Zhang; Ke-Shuai Dong; Er-Lei Zhang; Li-Wei Zhang; Xiao-Ping Chen; Han-Hua Dong
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

7.  Case report: Urgent liver pathologies: All in one.

Authors:  Goran Pavlek; Ivan Romic; Kristina Juzbasic; Ana Marija Alduk; Igor Petrovic; Rudolf Radojkovic; Dario Grbavac; Hrvoje Silovski
Journal:  Front Surg       Date:  2022-07-20

8.  Tumor vascularity and lipiodol deposition as early radiological markers for predicting risk of disease progression in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization.

Authors:  Cheng-Shi Chen; Fang-Kun Li; Chen-Yang Guo; Jin-Cheng Xiao; Hong-Tao Hu; Hong-Tao Cheng; Lin Zheng; Deng-Wei Zong; Jun-Li Ma; Li Jiang; Hai-Liang Li
Journal:  Oncotarget       Date:  2016-02-09

9.  The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.

Authors:  Fei-Xiang Wu; Jie Chen; Tao Bai; Shao-Liang Zhu; Tian-Bo Yang; Lu-Nan Qi; Ling Zou; Zi-Hui Li; Jia-Zhou Ye; Le-Qun Li
Journal:  BMC Cancer       Date:  2017-09-12       Impact factor: 4.430

10.  The degree of hepatic arterial blood supply of portal vein tumor thrombus in patients with hepatocellular carcinoma and its impact on overall survival after transarterial chemoembolization.

Authors:  Juxian Sun; Jie Shi; Bin Huang; Fantian Cheng; Weixing Guo; Wan Yee Lau; Shuqun Cheng
Journal:  Oncotarget       Date:  2017-08-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.